Insider · CIK 0001889522
Carey Ng
Files at IMMX (Immix Biopharma, Inc.). First filing -, latest -.
In brief
Carey Ng files SEC Form 4 as director at IMMX (Immix Biopharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Carey Ng has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | IMMX Immix Biopharma, Inc. | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 26,250 | May 29, 2026 |
| May 22, 2026 | IMMX Immix Biopharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +12,500 | $0.00 | $0 | 12,500 | May 29, 2026 |
| Jun 20, 2025 | IMMX Immix Biopharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 23, 2025 |
Questions about Carey Ng
Answered from the filings on this page, as of the latest one.
Is Carey Ng buying or selling?
Carey Ng has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Carey Ng's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Carey Ng has 0.
Where does Carey Ng file Form 4?
Carey Ng has filed Form 4 at IMMX (Immix Biopharma, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.